Analysis of Hepatotoxicity Associated With TKIs in Solid Tumors

Tanios S. Bekaii-Saab, MD, describes the common adverse events associated with each type of tyrosine kinase inhibitor (TKI), which are specific to the targets hit by that TKI and commonly include fatigue and hepatotoxicity.

Tanios S. Bekaii-Saab, MD, describes the hepatotoxicity commonly seen with tyrosine kinase inhibitors (TKIs) and how to monitor and detect it with aspartate aminotransferase (AST) and alanine transaminase (ALT).

Liver injury can occur within 2 weeks of starting therapy with a tyrosine kinase inhibitor, although it can also be seen as late as 2 months, describes Tanios S. Bekaii-Saab, MD, making vigilance key for proper mitigation of this adverse event.

Tanios S. Bekaii-Saab, MD, discusses minimizing the toxicities associates with tyrosine kinase inhibitors (TKIs) through dose optimizations strategies, which are of particular interest at TKIs are combined with immune checkpoint inhibitors that also may impact the liver.

Tanios S. Bekaii-Saab, MD, provides insight into ongoing research exploring novel combinations of tyrosine kinase inhibitors and immune checkpoint inhibitors across solid tumors.

Tanios S. Bekaii-Saab, MD, describes the future direct of clinical research into immune check point inhibitors for solid tumors, which he believes will be to explore additional combinations with targeted therapies.